Date: 26 November 2013
Secondary metabolites, 3D structure: Trivial name – citreoviridin
Copyright: n/a
Notes:
Species: A. terreusSystematic name: D-Iditol, 2,5-anhydro-1,6-dideoxy-2-C-[(1E,3E,5E,7E)-8-(4-methoxy-5-methyl-2-oxo-2H-pyran-6-yl)-2-methyl-1,3,5,7-octatetraenyl]-4-C-methyl- (9CI)Molecular formulae: C23H30O6Molecular weight: 402.481Chemical abstracts number: 25425-12-1Selected references: Franck B, Gehrken HP. Angew Chem Int Ed Engl. 1980;19(6):461-2 Citreoviridins from Aspergillus terreus.Toxicity: Citreoviridin is produced by P. citreonigrum (synonyms P. citreoviride and P. toxicarium), particularly in rice after harvest. It can cause cardiac beriberi in man. Acute cardiac beriberi in Japan is now only of historical interest although P. citreonigrum and citreoviridin are still reported in other parts of Asia. The fungus is said to be favoured by the lower temperatures and shorter hours of daylight occurring in the more temperate rice growing areas. The toxin is also produced by P. ochrosalmoneum. Citreoviridin has been found in un-harvested corn in the USA. Citreoviridin is an unusual molecule consisting of a lactone ring conjugated to a furan ring, with a molecular weight of 402. It is a neurotoxin. Nishie K, Cole RJ, Dorner JW. Res Commun Chem Pathol Pharmacol. 1988 Jan;59(1):31-52.Toxicity of citreoviridin.
Images library
-
Title
Legend
-
Patient with chronic productive cough, chest pain and ABPA, unable to take itraconazole or nebulised amphotericin B. Smokes at least 40 roll up cigarettes a day.
, 
-
Laryngeal aspergillosis, probably related to inhaled corticosteroids.
, 
, 
, 
-
VL-2397 (formerly known as ASP2397) is a novel antifungal drug initially developed by our partner, Astellas Pharma. This drug was isolated from a leaf litter fungus Acremonium species collected in a Malaysian national park. Astellas presented two posters at the 2014 ICAAC meeting which described the in vitro and the in vivo antifungal activities of this drug. The differentiating attributes from the preclinical data of VL-2397 include:
- A novel mechanism of action, with a potential to be complementary or synergistic with the existing classes of antifungals.
- Rapid fungal cell kill activity demonstrated in preclinical models, which was faster than marketed antifungals.
- Activity against azole-resistant fungal species.
- Low propensity for P450 drug-drug interactions.
-
SCY-078, new orally available beta-1,3-d-glucan synthase inhibitor, Formely MK-3118.
-
Pt DSM Community acquired primary Aspergillus pneumonia. Two x-rays taken on 02/02/2010 then 05/03/2010
, 
, 
